| 摘要 |
<p>The present inventors have found that the level of aberrantly glycosylated IgGs in serum is correlated to the development of cancer. More specifically, the present inventors have found that the ratio of aberrantly glycosylated IgGs versus normal IgGs is significantly increased in cancer patients compared with normal individuals, and that such ratio increases as the cancer progresses. The present inventors have also found that the majority (up to 85%) of the tumor-reactive IgGs in cancer patients are aberrantly glycosylated. In addition, the present inventors have isolated a switching factor that induces the production of aberrantly glycosylated IgGs from antibody-producing cells. Based on these findings, the present invention provides novel methods and compositions useful for diagnosing and treating cancers.</p> |
